Skip to content

Brain Oximeter Calibration and Validation Study

Cyban Brain Pulse Oximeter Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05397704
Acronym
TPOT
Enrollment
21
Registered
2022-05-31
Start date
2022-10-10
Completion date
2022-11-15
Last updated
2023-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries, Traumatic

Keywords

hypoxia

Brief summary

The purpose of the study is to calibrate and to validate the accuracy of the oximeter with an estimate of brain oxygen levels assessed by measuring arterial and internal jugular vein blood oxygen saturations.

Detailed description

The device is a non invasive NIRS monitor. It detects signals from which are derived venous and arterial blood brain oxygen levels. The device will be used as a adjunct monitor in patients with a brain injury or at risk of a brain injury. The primary objective of the study is to measure the absolute and relative accuracy of the StO2 device by comparing the NIRS-derived brain tissue oxygen saturation with blood-referenced CO-oximeter oxygen saturation values. The CO-oximeter oxygen saturation values from paired arterial and internal jugular venous blood gas samples are then inserted into a weighted-equation to derive the calculated brain tissue oxygen saturation. Accuracy is reported over a range of oxygen saturations with study subjects exposed to a controlled oxygen desaturation with serial sampling of paired arterial and internal jugular venous blood gas samples.

Interventions

brain oxygen monitoring during hypoxia

Sponsors

Duke University
CollaboratorOTHER
Cyban Pty Ltd
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Single group assignment

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy, male or female subjects between the ages of 18 to 45 years; * Completion of a health screening for a medical history by a licensed physician, nurse practitioner, or physician assistant; * Minimum weight 40kg; * BMI within range 18.0 - 35.0; * Assigned American Society of Anesthesiologists (ASA) Physical Status 1 by Principal Investigator or delegate

Exclusion criteria

* Prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., Novocain) \[self- reported\]; * Prior known severe allergies to medical grade adhesive/tape (Band-Aid) \[self-reported\]; * Taking any medication other than birth control\[self-reported\]; * Is currently participating in, or has recently participated in (discontinued within 30 days prior to the hypoxia procedure for this study) in an investigational drug, device, or biologic study \[self- reported\]; * Has a negative Allen's Test to confirm non- patency of the collateral artery \[clinical assessment by PI or delegate\]; * Has made a whole blood donation or has had at least 450 ml of blood drawn within 8 weeks prior to the study procedure \[self-reported\]; * Is female with a positive pregnancy test \[serum or urine\], or is female and is unwilling to use effective birth control between the time of screening and study procedure or is breast feeding; * Has anemia \[lab values specific for gender\]; * Has heparin allergy * Has a history of sickle cell trait or thalassemia \[self-reported\]; * Has an abnormal hemoglobin electrophoresis result \[lab measurement\]; * Has a positive urine cotinine test or urine drug screen or oral ethanol test; * Has a room air saturation less than 95% by pulse oximetry \[measurement by PI or delegate\] * Has a clinically significant abnormal EKG \[assessment by PI or delegate\]; * Has a clinically significant abnormal pulmonary function test via spirometry \[assessment by PI or delegate\]; * Has a COHb greater than 3%, or MetHb greater than 2% \[measured by venous blood sample co- oximetry\].

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of brain pulse oximeterData will be collected over a 90 minute period for each patientBland Altman analysis

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026